In a Review now online, @NicoleKuderer, @ADesaiMD, @maryam_lustberg and @gary_lyman explain the most common acute toxicities in patients with cancer receiving chemotherapy and discuss management options: nature.com/articles/s4157…
NatureRevClinOncol
14.5K posts
NatureRevClinOncol
@NatRevClinOncol
The latest clinical diagnostic, treatment & personalized medicine advances & more from Nature Reviews Clinical Oncology, a reviews journal.
- The #7 most visited long article published in @NatRevClinOncol in 2022 is: nature.com/articles/s4157…
- In a Review now published online, Mikael Pittet, Olivier Michielin & Denis Migliorini discuss the clinical relevance of macrophages in cancer, both as biomarkers and in therapeutic approaches nature.com/articles/s4157…
- In a new Review @AndrewChowMDPhD @KarloPerica @KlebanoffLab & @wolchokj discuss the immunobiology and clinical implications of T cell exhaustion for cancer immunotherapy: nature.com/articles/s4157… @MSKCancerCenter @WeillCornell
- In a new Review online in time for weekend reading, Wolf Fridman and colleagues discuss 'B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome': nature.com/articles/s4157… #ImmunoOnc #camicroenv
- In a Review now published online, @RohanKatipally @SeanPitroda @ajuloorimd @Docace911 and @rweichselbaum provide the current knowledge on oligometastatic cancer #metastasis nature.com/articles/s4157…
- In a Review now online, Patricia Steeg discusses the role of the blood–tumour barrier in cancer biology and therapy nature.com/articles/s4157…
- New Review by Douglas Johnson, Caroline Nebhan, Javid Moslehi (@CardioOncology) & Justin Balko now live online: 'Immune-checkpoint inhibitors: long-term implications of toxicity' nature.com/articles/s4157… #ImmunoOnc #medonc
- This new Review describes the roles of dendritic cells (DCs) as orchestrators of anticancer immunity, focusing on novel insights on DC heterogeneity gleaned from single-cell studies & how this knowledge might be leveraged to improve immunotherapy: nature.com/articles/s4157…
- In the phase III externally controlled trial of autologous tumour lysate-loaded DC vaccination (DCVax-L) vs SoC for newly diagnosed or recurrent glioblastoma demonstrates promising median OS durations & meaningful increases in the tails of the OS curves:
- In a new Perspective, Walia, Tuia & @VPrasadMDMPH discuss the adoption of composite end points in oncology, their pro and cons, and advocate for separate reporting of component events to enable a better understanding of cancer biology and trial results: nature.com/articles/s4157…
